Journal Articles

Disclaimer: The papers below are intended for private viewing by the page owner or those who otherwise have legitimate access to them. No part of it may in any form or by any electronic, mechanical, photocopying, recording, or any other means be reproduced, stored in a retrieval system or be broadcast or transmitted without the prior permission of the respective publishers. If your organization has a valid subscription of the journals, click on the DOI link for the legitimate copy of the papers.

Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions J Clin Pharm Ther 2019;44(3):361-371

Clinical considerations about opioid withdrawal symptoms Pain Manag 2019; 9(2):111-113

Using opioid therapy for pain in clinically challenging situations: questions for clinicians Minerva Anesthesiol 2019; 85(8):899-908

E-cigarettes for smoking cessation: do they deliver? J Clin Pharm Ther 2019;44(4):650-655

Three years down the road: the aftermath of the CDC guideline for prescribing opioids for chronic pain Adv Ther 2019;36(6):1235-1240

Pain Control in Latin America: The Optimized Role of Buprenorphine in the Treatment of Cancer and Noncancer Pain Pain. Pain Ther 8, 187–201 (2019)

Stopping of decreasing opioid therapy in patients on chronic opioid therapy Pain Ther. 2019 Dec;8(2):163-176

Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus Adv Ther 36, 2618–2637 (2019)

Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain Pain Ther 2018;7(1):37-57

Driving under the influence of opioids: what prescribers should know J Opioid Manag 2018;14(6):415-427

The Role of Lofexidine in Management of Opioid Withdrawal Pain Ther 2019;8(1)67-78

Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 3 – application of human factors engineering to an ozone hand sanitizer Pharmacol Pharm 2018;9:324-330

Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 2 – human factors Pharmacol Pharm 2018;9:310-323

Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 1 – biological and treatment factors Pharmacol Pharm 2018;9:293-309

The Place of Community Rescue Naloxone in a Public Health Crisis of Opioid Overdose Pharmacol Pharm 2019, 10, 61-81

Hormone replacement therapy for restoring the HPG axis in pain patients treated with long-term opioid analgesics Pharmacol Pharm 2018;9:473-480

‘New-look’ opioids: biased ligands Pharmacol Pharm 2018;9:242-249

Crisaborole and apremilast: pde4 inhibitors with similar mechanism of action, different indications for management of inflammatory skin conditions Pharmacol Pharm 2018;9:357-381

Differences in the receptor binding profile of lofexidine compared to clonidine Pharmacology & Pharmacy, 2019, 10, 1-10

Targets to watch – nerve growth factor (NGF) as a target for the treatment of neuropathic pain Drugs Future 2018;43:655-664

The fist approved ‘deuterated’ drug: a short review of the concept Pharmacol Pharm 2018;9:440-446

The role of medical literature, clinical trials and experimental research in drug product-injury litigation: a primer with two examples Pharmacol Pharm 2018;9:208-227

Cannabinoid Hyperemesis. Medical Cannabin and Cannabinoids Med Cannabis Cannabinoids 2018;1:73–95

Effectiveness of once-daily extended-release hydrocodone in individuals previously receiving immediate-release oxycodone for chronic pain Pain Med 2018;19(5):967-977

The fentanyl family: a distinguished medical history tainted by abuse J Clin Ther. 2018;43(1):154-158

Management of acute pain in the postoperative setting: the importance of quality indicators Curr Med Res Opin 2018; 34(1):187-196

The rapid-onset antidepressant effect of ketamine: More surprises? J Clin Pharm Ther 2018;43(2):308-311

Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances and street heroin Postgrad Med 2018. 130(1):1-8

Pharmacokinetics of oral and intravenous paracetamol (acetaminophen) when co-administered with intravenous morphine in healthy adult subjects Clin Drug Investig. 2018. 38(3):259-268

Abuse-deterrent opioids: an update on current approaches and considerations Curr Med Res Opin 2018;34(4):711-723

The role of cannabinoids in pain control: the good, the bad, and the ugly Minerva Anestesiol 2018 84(8):955-969

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release products J Pain Res. 2018;11:301-311

Pain chronification: what should a non-pain specialist know? Curr Med Res Opin 2018; 34(7):1169-1178

Nature’s first atypical opioids: kratom and mitragynines J Clin Pharm Ther 2018;43(3):437-441

The role and mechanism of action of menthol in topical analgesic products J Clin Pharm Ther 2018; 43(3):313-319

Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain Pain Ther 2018; 7(1):37-57

Transdermal buprenorphine for moderate chronic noncancer pain syndromes Expert Rev Neurother 2018; 23:1-11

Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs) J Clin Pharm Ther. 2018 Aug;43(4):443-449.

Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia J Clin Pharm Ther 2018. 43(4):460-464

What’s holding back abuse-deterrent opioid formulations? Considering 12 US stakeholders Exp Opin Drug Deliv 2018; 15(6):567-576

Discovery of folded DNA structures in human cells: potential drug targets J Clin Pharm Ther 2019; 44(1):125-128

Designing safer analgesics: a focus on µ opioid receptor pathways Exp Opin Drug Discov 2018; 13(10)965-972

Tapering opioid therapy: clinical strategies Pain Manag 2018;8(6):409-413

Sunscreen bans: coral reefs and skin cancer J Clin Pharm Ther. 2018; 44(1):134-139

The “Darknet”: The new street for street drugs J Clin Pharm Ther. 2017 Dec;42(6):790-792

Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure J Clin Aesthet Dermatol. 2017 May;10(5):36-48

A multicentre evaluation of an opioid patient-provider agreement. Postgrad Med J. 2017 Oct;93(1104):613-617

Comparison of paracorporeal and continuous flow ventricular assist devices in children: preliminary results Eur J Cardiothorac Surg. 2017 Apr 1;51(4):709-714

Treatment for chronic low back pain: the focus should change to multimodal management that reflects the underlying pain mechanisms Curr Med Res Opin. 2017 Jul;33(7):1199-1210

Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study J Formos Med Assoc. 2017 Apr;116(4):257-265

Role Of Anesthetist In Sedation For Diagnostic Procedures: The Glass Is Half Empty? A Narrative Review SOJ Anesthesiol Pain Manag. 2017 4(2): 1-4

Trigeminal Trophic Syndrome: A Case Report Austin J Anesthesia and Analgesia - Volume 5 Issue 2 - 2017

The Evolution of Abuse-Deterrent Extended-Release Opioid Formulations: Is there a Place in the Armamentarium for More Products? EC Anaesthesia 3.2 (2017): 64-77

Opioid Therapy for Chronic Noncancer Pain: Safe, Effective, Appropriate? Kaye AD, ed. Scientific American Pain Management [online]. Hamilton: Decker; January 2017

Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 2017 Mar;79(3):467-477

Efficacy and safety of once-daily extended-release (ER) hydrocodone in individuals previously receiving ER morphine for chronic pain Pain Pract. 2017 Mar; 17(3):382-391

Long-term effectiveness of once-daily, single-entity, extended-release hydrocodone in patients of ≥ 75 years of age with moderate to severe nonmalignant and nonneuropathic pain Geriatr Nurs. 2017 Jan-Feb; 38(1):39-47

Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies Drug Deliver Transl Res. 2017 Feb; 7(1):1-10

Safety of buprenorphine transdermal system in the management of pain in older adults Postgrad Med. 2017 Jan; 129(1):92-101

Peripherally acting µ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy Patient Pref Adherence 2017 Jan 17; 11:107-0119

Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting Cancer Chemother Pharmacol 2017 Mar; 79(3):467-477.

Treatment for chronic low back pain: the focus should change to multimodal management that reflects the underlying pain mechanisms Curr Med Res Opin 2017 Feb 22

Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study J Formos Med Assoc. 2016 Dec 23

Pain Specialists Awareness of Topical Analgesics and Their Use in Pain Control: Survey Results. (2016) J Anesth Surg 3(3): 1- 5

(2016) Insights into Chronic Postsurgical Pain. Int J Surg Res. 3(5), 55-60

The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused? J Clin Pharm Ther. 2016 Dec; 41(6):592-593

Change Pain: Ever Evolving-An Update for 2016 Pain Ther. 2016 Oct 14

Perspectives on Intravenous Oxycodone for Control of Postoperative Pain Pain Pract. 2016 Sep;16(7):924-34

Comments and Suggestions from Pain Specialists Regarding the CDC’s Proposed Opioid Guidelines Pain Pract. 2016 Sep;16(7):794-808

Knowledge, Attitude and Practice Survey of Prescribing Opioids for Chronic Noncancer Pain in Taiwan-Comparison of Pain and Non-Pain Physicians Pain Med. 2016 Aug 22. pii: pnw189

Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies Drug Deliv Transl Res. 2016 Aug 25

Good clinical practice guide for opioids in pain management: the three Ts – titration (trial), tweaking (tailoring), transition (tapering) Rev Bras Anestesiol. 2016 May-Jun; 66 (3):310-7

Good clinical practice guide for opioids in pain management: the three Ts – titration (trial), tweaking (tailoring), transition (tapering). Anesthesiol. 2016 May-Jun; 66 (3):310-7.

Evolution to low-dose NSAID therapy. Pain Manag. 2016 Apr;6(2):175-89

A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain Front Pharmacol. 2016 Mar 1;7:42

Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials Pain Pract. 2016 Mar;16(3):345-58

Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs J Clin Pharm Ther. 2015 Dec;40(6):615-9

The role of abuse-deterrent formulations in countering opioid misuse and abuse J Clin Pharm Ther. 2015 Dec;40(6):629-34

Improving the management of post-operative acute pain: priorities for change Curr Med Res Opin. 2015 Nov;31(11):2131-43

Postoperative Pain Surveys in Italy from 2006 and 2012: (POPSI and POPSI-2) Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4261-9.

Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management? Agri. 2015;27(1):1-11

New care measures and their impact on pain medicine: One pain specialist’s perspective Postgrad Med. 2015 Aug;127(6):616-22.

Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials Pain Pract. 2015 Jul;15(6):564-71

The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015 Jun;53(2):71-6.

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain Adv Ther. 2015 Jun;32(6):485-95

Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency J Opioid Manag. 2015 May-Jun;11(3):211-27

Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015 May 8;8:229-38

A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression. Pain Pract. 2015 Apr 11

Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract. 2015 Apr; 15(4):378-88

The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism Ther Clin Risk Manag. 2015 Mar 31; 11:515-23

Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain. Expert Rev Neurother. 2015 Mar; 15(3):231-8

DEA reschedules hydrocodone combination products Pain Pract. 2015 Feb; 15(2):95-7

Predicting medication persistence to buprenorphine transdermal system. Pain Pract. 2015 Feb;15(2):140-9

Ketorolac tromethamine – routes and clinical implications Pain Pract. 2015 Feb;15(2):175-93

Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management? Agri. 2015 Jan; 27(1):1-11

Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials Pain Pract. 2015 Jan 20

Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain Postgrad Med. 2015 Jan; 127(1):38-45

Treatment Considerations for Cancer Pain: A Global Perspective Pain Pract. 2014 Dec 3.

Antioxidant and associated capacities of camu (Myrciaria dubia): a systematic review. J Altern Complement Med. 2015 Jan; 21(1):8-14

Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients Pain Med. 2014 Dec; 15(12):2087-94.

Regional anesthesia techniques for carotid surgery: the state of art J Ultrasound. 2014 May 1; 17(3):175-83

Acute pain: effective management requires comprehensive assessment Postgrad Med. 2014 Jul; 126(4):59-72

Opioid formulations with sequestered naltrexone: a perspective review Ther Adv Drug Saf. 2014 Jun; 5(3):129-37.

The clinical analgesic efficacy of buprenorphine J Clin Pharm Ther. 2014 Dec; 39(6):577-83

‘Selective’ COX-1 or COX-2 NSAIDs: time to change a misleading measure J Clin Pharm Ther. 2014 Oct; 39(5):455-6

Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: results of in vitro laboratory analyses J Opioid Manag. 2014 May-Jun; 10(3):149-58

Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity Expert Opin Drug Saf. 2014 Jul; 13(7):903-17

Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements Curr Med Res Opin. 2014 Sep; 30(9):1895-908

Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials Pain Pract. 2014 May 10

The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting Front. Pharmacol., 09 April 2014

A modern analgesics pain ‘pyramid’ J Clin Pharm Ther. 2014 Feb; 39(1):4-6

The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health Clin J Pain. 2014 Dec; 30(12):1015-22

New health care measures: emphasis on better management of postsurgical pain and postoperative nausea and vomiting Hosp Pract (1995). 2014 Feb; 42(1):65-74

Treating acute pain in light of the chronification of pain Pain Manag Nurs. 2014 Mar; 15(1):380-90

Pain and obesity in the older adult Curr Pharm Des. 2014; 20(38):6037-41

Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness Sleep Disord. 2014; 2014:527109

The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients J Manag Care Spec Pharm. 2014 May; 20(5):467-76

US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system Curr Med Res Opin. 2014 Aug; 30(8):1579-87

Ketorolac tromethamine – routes and clinical implications Pain Pract. 2015 Feb; 15(2):175-93

Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum. J Pain Res. 2013 Dec 4; 6:791-801

Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives Curr Med Res Opin. 2013 Oct 28

Sequestered naltrexone in sustained release morphine or oxycodone – a way to inhibit illicit use? Expert Opin Drug Saf. 2013 Nov 11

Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients? Pain Manag Nurs. 2013 Sep; 14(3):e67-83

Abuse-Deterrent Formulations of Opioid Analgesics Pain Pract. 2013 Aug 6

The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment Curr Med Res Opin 2013 Jul 3

Low Back Pain in a Natural Disaster Pain Pract. 2013 Jun 14

The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs Value Health. 2013 May; 16(3):A12

Factors predicting medication persistence among patients initiating Buprenorphine transdermal system Value Health. 2013 May; 16(3):A120

Impact of dosage strength on medication persistence among patients treated with buprenorphine transdermal system. Value Health. 2013 May; 16(3):A120

Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging. 2012 Dec; 29(12):993-5; author reply 997-8

Essential Oxygen Oil for Treatment of Sport-Related Injuries American Journal of Sports Science and Medicine, 2013, Vol. 1, No. 1, 7-12

Tramadol/Paracetamol Fixed-Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review ISRN Family Medicine, vol. 2013, Article ID 638469, 15 pages, 2013

Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis Pain. 2013 Jan 11. pii: S0304-3959(13)00009-2.

Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber Nursing: Research and Reviews 2013:3

An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult J Opioid Manag. 2012 Nov-Dec; 8(6):383-93

Pain treatment in arthritis-related pain: beyond NSAIDs Open Rheumatol J. 2012; 6:320-30.

Tapentadol extended release for chronic pain patients. Adv Ther. 2013 Jan; 30(1):14-27

Compounding Pharmacies: Who is in Charge? Pain Pract. 2013 Jan 28

Treatment of Chronic Pain in Older People: Evidence-Based Choice of Strong-Acting Opioids Drugs Aging. 2012:12 (29): 993-95.

Es la Buprenorfina una buena opción en el manejo de dolor postoperatorio? Rev Soc Esp Dolor 2012; 19(6): X-X

A Randomized, Placebo-Controlled Study of the Impact of the 7-Day Buprenorphine Transdermal System on Health-Related Quality of Life in Opioid-Naïve Patients with Moderate-to-Severe Chronic Low Back Pain The Journal of Pain, Vol 13 No (1), 2013: pp 14-23

Designing Opioids That Deter Abuse Pain Research and Treatment 2012, Article ID 282981

Transversus Abdominis Block: Clinical Uses, Side Effects, and Future Perspectives Pain Pract. 2012 Sep 12.

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain Journal of Pain Research 2012:5 327–346

Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine Pain Physician. 2012 Jul; 15(3 Suppl):ES59-66

Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting J Clin Anesth. 2012 Jun; 24(4):334-45

Dynamic risk factors in the misuse of opioid analgesics J Psychosom Res. 2012 Jun; 72(6):443-51. Epub 2012 Apr 5

A Review of Duloxetine 60 mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain. Pain Pract. 2012 Jun 21

Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse-Deterrent Formulations. Curr Pharm Des. 2012 Jun 28.

Pain after earthquake Scand J Trauma Resusc Emerg Med. 2012 Jun 29; 20(1):43

Is Morphine Medicine’s Biggest Misnomer? Ann Pharmacother. 2012 Jul 3

Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature J Pain Res. 2012; 5:77-87. Epub 2012 Apr 23

QTc interval prolongation by d-propoxyphene: what about other analgesics? Expert Opin Pharmacother. 2012 May 9

Fixed-dose combinations for emerging treatment of pain Expert Opin Pharmacother. 2012 Mar 16

Low-dose transdermal buprenorphine system: an update Paineurope 2012: 1; 8-9

Intracerebroventricular opioids for intractable pain Br J Clin Pharmacol. 2012 Feb 1

Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel’s View on Preventable Harm Associated with NSAID Therapy Current Gerontology and Geriatrics Research, vol. 2012, Article ID 196159, 9 pages, 2012

Multi-mechanistic analgesia for opioid-induced hyperalgesia. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 125–127

The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors? Curr Med Res Opin. 2011 Dec 19

Naltrexone extended-release injection: an option for the management of opioid abuse Substance Abuse and Rehabilitation 2011:2; 219–226

Quantifying the Impact of Drug-Drug Interactions Associated with Opioids The American Journal of Managed Care. 2011:17 (11). (S) 288-292

Chronic pain – moving from symptom control to mechanism-based treatment Current Medical Research & Opinion 2011: 27(10): 2079–2080

Clinical Roundup: How Do You Treat Premenstrual Syndrome in Your Practice? Alternative and Complementary Therapies. August 2011, 17(4): 237-246

Conference report Proceedings of the CHANGE PAIN Expert Summit in Rome, June 2011 Current Medical Research & Opinion 2011: 27 (10): 2061–2062

Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol Pain Pract. 2011 Jul 29

Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? Journal of Pain Research 2011:4: 203–210

Prophylaxis of Postoperative Nausea and Vomiting in Adolescent Patients: A Review with Emphasis on Combination of Fixed-Dose Ondansetron and Transdermal Scopolamine Journal of Drug Delivery Volume 2011, Article ID 426813, 7 pages

Continuous Multimechanistic Postoperative Analgesia: A Rationale for Transitioning from Intravenous Acetaminophen and Opioids to Oral Formulations Pain Pract. 2011 Jun 16

Perspectives on the Role of Fospropofol in the Monitored Anesthesia Care Setting Anesthesiology Research and Practice, vol. 2011, Article ID 458920

“Extended-release Formulations of Tramadol in the Treatment of Chronic Pain” In Press: Expert Opin Pharmacother. 2011:12 (11)

In response: urine drug screening and compliance Pain Pract. 2011 Mar; 11(2):199

Casopitant and Ondansetron for Postoperative Nausea and Vomiting Prevention in Women at High Risk for Emesis: A Phase 3 Study. Arch Surg. 2011; 146(2):201-206

Exposure to Potential CYP450 Pharmacokinetic Drug–Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions. Pain Practice Article first published online: 28 DEC 2010

Anesthetic Routines: The Anesthesiologist’s Role in GI Recovery and Postoperative Ileus Advances in Preventive Medicine Volume 2011, Article ID 976904, 10 pages

Bullying in middle school: Results from a 2008 survey Int J Adolesc Med Health 2011; 23(1):11–18

The evolving understanding of the analgesic mechanism of action of flupirtine. Journal of Clinical Pharmacy and Therapeutics (2010) Article first published online: 28 NOV 2010

Commentary Make a CHANGE: optimizing communication and pain management decisions. Current Medical Research & Opinion Vol., No. , 2011, 1–8

Transdermal Scopolamine for the Prevention of Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis Clinical Therapeutics. Vol. 32, No.12, 2010, 1-15.

The impact of pain on labor force participation, absenteeism and presenteeism in the European Union Journal of Medical Economics Vol. 13, No. 4, 2010, 662–672

Opioid Formulations Designed to Resist/Deter Abuse Drugs. 70(13):1657-1675, September 10, 2010

Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug – Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids. Pain Practice Article first published online: 26 AUG 2010

Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example In Press: Journal of Clinical Pharmacy and Therapeutics (2010).

The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization Journal of Medical Economics Vol. 13, No. 3, 2010: 571-581

The Determination and Application of Fixed-Dose Analgesic Combinations for Treating Multimodal Pain The Journal of Pain, 2010: 11(8): 701-709

Restoration of disc height through non-invasive spinal decompression is associated with decreased discogenic low back pain: a retrospective cohort study BMC Musculoskeletal Disorders 2010, 11:155

Oxycodone combinations for Pain Relief Drugs of Today 2010, 46(6): 379-398

Cohort study finds nine times increased overdose risk (fatal plus non-fatal) in patients receiving 100 mg/day for 90 days compared with 1-20 mg/day opioids for chronic non-cancer pain, but wide CI and possibility of unmeasured confounders Evid Based Nurs. 2010; 13(2):55-6.

Management of Opioid Tolerability and Related Adverse Effects Journal of Medicine 2010; 3(1):1–10

Preliminary Observations of a Novel Topical Oil with Analgesic Properties for Treatment of Acute and Chronic Pain Syndromes Pain Practice 2010:3; 201-213

European perspectives on upcoming analgesics: What do they have that we don’t—and what do they think about them? Techniques in Regional Anesthesia and Pain Management 2010:14; 86-98.

The Role of Urine Drug Testing for Patients on Opioid Therapy Pain Pract. 2010; 10(6):497-507

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Post discharge Nausea and Vomiting in High-risk Patients Anesthesiology 2010; 113:1–1

Pharmacological treatment of chronic pain – the need for CHANGE. Current Medical Research and Opinion 2010: 26(5): 1231-1245

The Use of High-Dose Transdermal Buprenorphine in the Treatment of Cancer Pain J. Med 2009; 2(2):111–120

Considerations on the use of oxymorphone in geriatric patients Expert Opin. Drug Saf. (2009) 8(5).

The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus Current Medical Research and Opinion 25:6: 2009, 1517–1528

A Randomized, Double-Blind, Multicenter Trial Comparing Transdermal Scopolamine Plus Ondansetron to Ondansetron Alone for the Prevention of Postoperative Nausea and Vomiting in the Outpatient Setting Anesth Analg 2009; 108:1498 –504

Oxymorphone and Opioid Rotation Pan Medicine. 2009:10 ;( S1): S39-48

Therapeutic Decision Support and the Management of Post-Operative Nausea and Vomiting J. Med 2009; 2(1):62-67

The Quantification and Tracking of Osteoarthritis J. Med 2009; 2(1):23-29

Two-Year Survey of Bullying in American Middle Schools J. Med 2009: 2(1); 45-51

Patients Who Smoke: To Cut or Not to Cut J. Med 2009; 2(1):56-61

Non-surgical Spinal Decompression (DRX9000TM) for the Treatment of Chronic Low Back Pain – Case Report European Musculoskeletal Review, 2008; 3: 2, 58-60

Growth hormone replacement for adults: an overview. J Med. September 2008:9–15

Prospective evaluation of the efficacy of spinal decompression via the DRX9000 for chronic low back pain J Med. September 2008:2–8.

Management of discogenic low-back pain with a non-surgical decompression system (DRX9000™)—Case Report US Musculoskeletal Review, 2008;1:14-15

Management of low-back pain with a non-surgical spinal decompression system (DRX9000™) – case report European Musculoskeletal Review, 2008; 3:1; 59–60

Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone Pain Practice June 2008.

Treatment of 94 Patients with Chronic Discogenic Back Pain with the DRX9000: A Retrospective Chart Review Pain Practice. January 2008. Vol. 8, Issue 1 Page 11-17

The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer (2007) 15: 63–71

Anesthesiologists’ practice patterns for rescue treatment of postoperative nausea and vomiting in the ambulatory PACU BMC Anesthesiology 2006:6:6

Systematic literature review of spinal decompression via motorized traction for chronic discogenic low back pain Pain Practice. September 2006.Vol. 6 Issue 3 Page 171-178

Urine Drug Testing in Chronic Pain Patients Taking Opioids: A Clinical Practice Update The International Journal of Pain and Palliative Care 2005; 4(1): 133-9

Pain and Nausea Management after Surgery The International Journal of Pain and Palliative Care 2004; 3: 91-100

PONV Unplugged Seminars in Aesthesia, Perioperative Medicine and Pain, Vol 23, No 2 (June), 2004: pp 203-220

Organizational model for a clinical trials unit within an academic medical center Research Practitioner Volume 2, Number 2 March/April 2001:107-112

Essentials Elements of a Clinical Trials Unit/Center European Pharmaceutical Contractor. Feb 2000; 3: 96- 99

Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature Am Surg. May 1999; 65(5): 402-405

Merkel Cell Carcinoma: An Aggressive Malignancy American Surgeon 5/97 Vol. 63 Page 450-454